Trial Profile
A Phase II Study of Paclitaxel+S-1 for previously treated Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Aug 2016
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Jul 2016 Status changed from active, no longer recruiting to completed.
- 23 Jul 2012 Planned End Date changed from 1 Jun 2014 to 31 Dec 2013 as reported by University Hospital Medical Information Network - Japan.
- 15 Jun 2012 New trial record